Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
ROIV is expected to report earnings to fall 206.00% to -24 cents per share on June 25
Q1'25
Est.
$-0.24
Q4'24
Beat
by $0.48
Q3'24
Missed
by $0.02
Q2'24
Beat
by $0.36
Q1'24
Beat
by $0.09
The last earnings report on February 10 showed earnings per share of 23 cents, beating the estimate of -25 cents. With 93.71K shares outstanding, the current market capitalization sits at 7.19B.